The microbiological, clinical, and epidemiological features of most non-Candida albicans Candida species are well known, but much less is known about species such as Candida guilliermondii, an uncommon pathogen causing a variety of deep-seated
infections in immunocompromised hosts. To characterize C. guilliermondii
fungemia in patients with
hematological malignancies and its susceptibility to antifungal drugs, all cases of C. guilliermondii
fungemia diagnosed in our department between 1983 and 2005 were retrospectively analyzed and the literature was reviewed. C. guilliermondii caused 29/243 (11.7%)
candidemia episodes diagnosed during the study period.
Central venous catheters were the documented sources of
candidemia in 19/29 episodes (65.5%), and invasive tissue
infections were documented in 2 (6.9%). In the remaining eight, the
catheter was not removed and the source of the
fungemia remained obscure. Seven episodes ended in death, but only one could be attributed to invasive C. guilliermondii
infection. Molecular typing data reveal no evidence of common
infection sources. Isolates displayed high rates of in vitro susceptibility to
amphotericin B (100%),
voriconazole (95%), and
fluconazole (90%) and lower rates of in vitro susceptibility to
flucytosine (86%),
itraconazole (76%), and
caspofungin (33%). Our literature review confirms that C. guilliermondii is a significantly more frequent cause of
candidemia among
cancer patients compared with the general hospital population. It accounted for <1% of the total number of Candida bloodstream isolates reported in the articles we reviewed, with higher rates in Europe (1.4%) and Asia (1.8%) compared with North America (0.3%).